Firefly Neuroscience (AIFF) Common Equity (2010 - 2026)

Firefly Neuroscience's Common Equity history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• On a quarterly basis, Common Equity rose 62.82% year-over-year to $8.4 million in Q1 2026; TTM through Mar 2026 was $8.4 million, a 62.82% increase from a year earlier, with the FY2025 full-year figure at $7.6 million, up 2136.53% from the prior year.
• Common Equity climbed to $8.4 million in Q1 2026 per AIFF's latest filing, from $7.6 million in the prior quarter.
• Across five years, Common Equity topped out at $15.7 million in Q1 2022 and bottomed at -$2.8 million in Q3 2024.
• The 5-year median for Common Equity is $2.4 million (2023), against an average of $4.7 million.
• Across the five-year window, Common Equity plunged 444.04% in 2024 and jumped 57711.11% in 2025, its largest moves.
• Year by year, Common Equity stood at -$2.2 million in 2022, then jumped by 104.9% to $109000.0 in 2023, then plunged by 444.04% to -$375000.0 in 2024, then surged by 2136.53% to $7.6 million in 2025, then increased by 10.54% to $8.4 million in 2026.
• Per Business Quant, the three latest AIFF Common Equity figures stand at $8.4 million (Q1 2026), $7.6 million (Q4 2025), and $9.7 million (Q3 2025).